HomeNewsIndiaJapan's Kirin to invest $30 million in India's Bira beer maker

Japan's Kirin to invest $30 million in India's Bira beer maker

The investment would allow Bira, which has posted losses in recent years and has been hit by the COVID-19 pandemic, to break even in the 2022 fiscal year which starts in April 2021, Ankur Jain said.

January 04, 2021 / 15:03 IST
Story continues below Advertisement
Image: Pexels
Image: Pexels

Amid falling stakes back home, Japan's beer maker Kirin Holdings is planning to invest $30 million in the maker of Bira 91, a popular Indian craft beer with bottles sporting sketches of a quirky monkey with a punk hairdo, the companies said on January 4.

The Japanese brewer plans to acquire a stake of under 10 percent in B9 Beverages, founded and led by New Delhi-based entrepreneur Ankur Jain, also a Kirin spokesman told news agency Reuters refusing to give further financial details.

Story continues below Advertisement

B9 had been in talks with international brewers - including Kirin - and other investors to sell a stake of up to 20 percent in the company, Reuters reported in August.

The investment would allow Bira, which has posted losses in recent years and has been hit by the COVID-19 pandemic, to break even in the 2022 fiscal year which starts in April 2021, Jain said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show